Google Platform Changes Spur Pharma Rethinking Of Search Engine Ads
This article was originally published in The Tan Sheet
Widespread use of paid ads that display disease-specific website address differing significantly from destination hyperlink for branded product will end in January.
You may also be interested in...
Click-through rate on health condition search results declined dramatically since FDA citations, company says.
Firms will need to redesign sponsored links that appear on Internet search engines or forgo using them at all, food and drug attorneys suggest following the agency's recent cluster of letters citing the promotions
In the EUA for Pfizer’s COVID-19 oral antiviral treatment, US FDA required a reduced dose for some renally impaired patients that is ‘incongruent with how Paxlovid is packaged,’ meaning that pharmacists have to manually make changes to each blister pack. Prescribers will have to navigate an extensive list of contraindicated medicines due to CYP3A effects.